Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of May 2025, with a report date of May 19, 2025. The filing serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The material change disclosed is a share purchase transaction by an Independent Non-Executive Director. On May 16, 2025, Bláthnaid Bergin purchased 6,145 ordinary shares of Haleon Plc at a price of £4.0427 per share on the London Stock Exchange (XLON). No other material changes to the company's operations or financial position are detailed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document focuses solely on the compliance notification of the PDMR transaction.
Key Facts for Investor Verification
- Transaction Date: May 16, 2025
- Insider: Bláthnaid Bergin (Independent Non-Executive Director)
- Action: Purchase of 6,145 Ordinary Shares
- Price: £4.0427 per share
- Exchange: London Stock Exchange (XLON)
- Instrument: Ordinary Shares of £0.01 each (ISIN: GB00BMX86B70)